- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Penpulimab, placebo
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Murrieta, California • Fairfax, Virginia
- Conditions
- Higher-risk Myelodysplastic Syndromes
- Interventions
- AK117, Placebo, Azacitidine
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Non-Squamous Non-small Cell Lung Cancer
- Interventions
- AK112 Injection, Placebo Injection
- Drug
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 43
- States / cities
- Bakersfield, California • La Jolla, California • Los Angeles, California + 35 more
- Conditions
- Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Interventions
- AK104
- Biological
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 19
- States / cities
- Newport Beach, California • Miami, Florida • Plantation, Florida + 16 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, AK120
- Drug
- Lead sponsor
- Akesobio Australia Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more
- Conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- Cadonilimab, CAPOX regimen, Nivolumab, Placebo
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 9 more